Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Serlopitant 0.25 mg vs placebo Adverse events · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | RR 1.29 [0.75, 2.24] | 1 study · 127 participants | Very low |
Serlopitant 0.25 mg vs placebo Health‐related quality of life · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | 1 study · 127 participants | Very low |
Serlopitant 0.25 mg vs placebo Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | RR 0.6 [0.31, 1.17] | 1 study · 127 participants | Very low |
Serlopitant 0.25 mg vs placebo Depression · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 0.25 mg vs placebo Patient satisfaction · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 5 mg vs placebo Adverse events · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | RR 1.48 [0.87, 2.5] | 1 study · 127 participants | Very low |
Serlopitant 5 mg vs placebo Health‐related quality of life · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | 1 study · 127 participants | Very low |
Serlopitant 5 mg vs placebo Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | RR 0.49 [0.24, 1.01] | 1 study · 128 participants | Very low |
Serlopitant 5 mg vs placebo Depression · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 5 mg vs placebo Patient satisfaction · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 1 mg vs placebo Patient‐reported pruritus intensity · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | RR 1.5 [0.89, 2.54] | 1 study · 126 participants | Low |
Serlopitant 1 mg vs placebo Adverse events · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | RR 1.45 [0.86, 2.47] | 1 study · 128 participants | Very low |
Serlopitant 1 mg vs placebo Health‐related quality of life · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | 1 study · 128 participants | Very low |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Tezepelumab (1 RCT; 56 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.65 [0.11, 3.77] | 1 study · 56 participants | Low |
Intervention NR Lebrikizumab (1 RCT; 156 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.85 [0.17, 4.25] | 1 study · 156 participants | Very low |
Intervention NR PF‐04965842 (1 RCT; 211 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.93 [0.2, 4.35] | 1 study · 4965842 participants | Very low |
Intervention NR Tralokinumab (1 RCT; 153 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 1.67 [0.2, 13.93] | 1 study · 153 participants | Very low |
Intervention NR Apremilast (1 RCT; 121 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 3.73 [0.2, 71.1] | 1 study · 121 participants | Low |
Intervention NR Baricitinib (1 RCT; 75 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 4.61 [0.24, 87.25] | 1 study · 75 participants | Very low |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Total studies: 6 RCTsTotal participants: 1720 · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 6 studies · 1720 participants | Ungraded |
Intervention NR Dupilumab (3 RCTs; 1082 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.68 [0.38, 1.21] | 3 studies · 1082 participants | Low |
Intervention NR Methotrexate (1 RCT; 50 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 1.15 [0.01, 151.54] | 1 study · 50 participants | Very low |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Fezakinumab (1 RCT; 40 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 2.56 [0.13, 50.95] | 1 study · 40 participants | Very low |
Intervention NR QGE031 (1 RCT; 10 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 3 [0.14, 65.9] | 1 study · 31 participants | Very low |
Intervention NR Cyclosporin A (2 RCTs; 49 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 3.67 [0.09, 149.2] | 2 studies · 49 participants | Very low |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Total studies: 13 RCTsTotal participants: 1658 · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 13 studies · 1658 participants | Ungraded |
Intervention NR Corticosteroid (1 RCT; 21 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.15 [0.01, 4.1] | 1 study · 21 participants | Very low |
Intervention NR Dupilumab (4 RCTs; 990 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.43 [0.18, 1.06] | 4 studies · 990 participants | Very low |
Intervention NR Cyclosporin A (3 RCTs; 74 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.75 [0.1, 5.75] | 3 studies · 74 participants | Very low |
Intervention NR Lebrikizumab (1 RCT; 156 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.79 [0.17, 3.79] | 1 study · 156 participants | Very low |
Intervention NR Timapiprant (1 RCT; 70 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.82 [0.16, 4.14] | 1 study · 70 participants | Low |
Intervention NR Total studies: 6 RCTsTotal participants: 2680 · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 6 studies · 2680 participants | Ungraded |
Intervention NR CIM331 (1 RCT; 27 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.87 [0.16, 4.63] | 1 study · 331 participants | Low |
Intervention NR GBR830 (1 RCT; 46 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 1.04 [0.12, 8.81] | 1 study · 830 participants | Low |
Intervention NR Azathiopine (AZA) (1 RCT; 41 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 1.14 [0.16, 8.11] | 1 study · 41 participants | Low |
Intervention NR QAW039 (1 RCT; 76 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 2.66 [0.34, 21.18] | 1 study · 39 participants | Very low |
Intervention NR CsAI (1 RCT; 40 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 3.57 [0.07, 182.64] | 1 study · 40 participants | Very low |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Dupilumab (5 RCTs; 1997 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 5 studies · 1997 participants | High |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Total studies: 17 RCTsTotal participants: 3972 · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 17 studies · 3972 participants | Ungraded |
Intervention NR QAW039 (1 RCT; 76 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.09 [0.01, 0.76] | 1 study · 39 participants | Moderate |
Intervention NR Dupilumab (9 RCTs; 1663 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.37 [0.23, 0.59] | 9 studies · 1663 participants | Low |
Intervention NR Timapiprant (1 RCT; 70 participants) · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | RR 0.34 [0.07, 1.62] | 1 study · 70 participants | Low |
Topical steroid plus topical antibiotic vs topical steroid Global outcome (good or excellent improvement in symptoms or signs, or both) · children and adults with eczema Interventions to reduce Staphylococcus aureus in the management of eczema (2019) · Cochrane | RR 1.1 [1, 1.21] | 3 studies · 224 participants | Low |
Oral antibiotic vs placebo Adverse events requiring withdrawal from treatment · children and adults with atopic dermatitis Interventions to reduce Staphylococcus aureus in the management of eczema (2019) · Cochrane | no estimate extracted | 4 studies · 199 participants | Very low |